According to Italian media reports, the struggle is comprehensively compiled in Italy: Recently, the American pharmaceutical giant Merck Pharmaceuticals MSD announced that the company has developed a pill called Molnupiravir, which can treat people infected with new crown .
(data map: Merck Pharmaceuticals)
According to the company's third phase research report, this drug can reduce the risk of hospitalization and death in high-risk groups by half, and it has been performed on 750 people. The third phase of the study showed that if the drug is taken in the early stages of infection, the risk of developing moderate or death will be reduced by 50%.
Moreover, this drug has a significant effect on the currently known Gamma, Delta and Mu viruses. The research team said that the drug must be taken for five days, four tablets per day, and then just stay at home "comfortably", without hospitalization or taking the drug under the supervision of a doctor.
reported that the working principle of the drug is very complicated. Simply put, it affects the RNA fragments of the virus and causes the virus to mutate, causing the virus to "error" and lose its toxicity.
According to data provided by Merck’s pharmaceutical partners, 7.3% of patients who used Molnupiravir were hospitalized or died within 29 days, while among those who received placebo, this proportion reached 14.1%. Therefore The effectiveness of this drug is 50%.
At present, Merck Pharmaceuticals has planned to apply to the U.S. Drug Administration FDA for emergency authorization as soon as possible, and apply to other regulatory agencies around the world. Currently Merck Pharmaceuticals has signed the first agreement with the U.S. government. Once the pill is authorized, the pharmaceutical company will provide 1.7 million doses of the drug to the United States to treat people with new crown infections.
and currently,The company has already begun producing such tablets, and its goal is to produce 10 million tablets by the end of this year.
Regarding the pricing of tablets, Merck Pharmaceuticals said that the price of this drug will be priced differently according to the income of each country, which can benefit more than 100 low- and middle-income countries around the world.
Gianni Rezza, Director of the Prevention Department of the Italian Ministry of Health, said: "I am confident, but still need to evaluate carefully. We already have vaccines and monoclonal antibody therapies available, but there is still a lack of antiviral drugs. To develop a Antiviral drugs for specific viruses are not easy. With antiviral drugs, we will have a series of tools that will allow us to fight the new coronavirus ."
In addition, the Italian CNR molecular genetics research Director Giovanni Maga said that the antiviral drugs produced by Merck can indeed represent a turning point in the fight against the new coronavirus. If used in the early stage after infection, it can reduce hospitalization. Strictly speaking, this is an antiviral drug, which currently seems to be very safe. (Struggle in Italy)
.
